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Abstract
Background: Soluble TNF superfamily (TNFSF) ligands are less stable and less active than their transmembrane (tm)
analogues. This is a problem for the therapeutic use of recombinant TNFSF ligands in diverse diseases including
cancer and autoimmunity. Creating TNFSF ligand analogues with improved targeting of their respective receptors is
important for research and therapeutic purposes.
Findings: Covalent internal cross-linking of TNF monomers by double mutations, S95C/G148C, results in stable trimers
with improved TNFR2 function. The resulting mutein induced the selective death of autoreactive CD8 T cells in type-1
diabetic patients and demonstrates targeted proliferation and expansion of human CD4 Tregs.
Conclusions: Stable TNF trimers, created by internal covalent cross-linking, show improved signaling. The high
structural homology within the TNF superfamily provides an opportunity to extend internal cross-linking to other
TNF superfamily proteins to produce active trimers with improved stability and receptor signaling, and with
potential applications for cancer, autoimmunity, infections, and transplantation.
Keywords: TNF, Trimer, Cell signaling, TNFR2, Transmembrane TNF, Tumor necrosis factor, Tumor necrosis factor
receptor
Findings
The tumor necrosis factor (TNF) superfamily, composed
of both ligands and receptors, is one of the most suc-
cessfully and frequently targeted protein families with
clinical relevance to diverse diseases as cancer, auto-
immunity, infections, graft rejection, inflammation and
osteoporosis [1, 2]. Depending on the clinical situation,
there is a need to both agonize and antagonize TNF
superfamily (TNFSF) pathways. Most TNF superfamily
(TNFSF) ligands are type II transmembrane proteins
that act through more than one receptor, and like TNF
can be cleaved to produce a soluble ligand that is less
effective at signaling. All TNFSF ligands share the TNF
homology domain and form non-covalent homotrimers
[3]. Ligand trimerization is essential for signaling by
TNFSF members. However, the trimers tend to dissoci-
ate at low concentrations such as in serum resulting in
their degradation. Creating stable trimers of TNF and
other TNFSF ligands is thus an essential step in generat-
ing functionally active receptor specific muteins [4, 5].
Various methods of secondary cross-linking of TNF
ligands are also desirable but have faced challenges in in-
creasing stability, half-life and improved signaling [6, 7].
Many TNF superfamily protein design approaches have
been based on the construction of fusion proteins [7].
TNF is a pleiotropic cytokine with diverse functions in
cell proliferation, inflammation, apoptosis and morpho-
genesis [1]. TNF is expressed as a tight trimeric trans-
membrane protein (tmTNF) that can be cleaved to
produce soluble TNF (sTNF) [8, 9]. tmTNF and sTNF
exert their functions via two receptors, TNFR1 and
TNFR2. TNFR1 is ubiquitously expressed in the lymph-
oid system and in nearly all cells of the body, whereas
TNFR2 has more limited cellular expression. sTNF binds
with high affinity to both TNFR1 and TNFR2 but signals
almost exclusively through TNFR1. Only tmTNF can
effectively activate TNFR2 [10]. The picture that emerges
from the literature indicates that the membrane serves
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at least two functions: 1) it anchors TNF, and increases
its stability and bioavailability; and 2) it provides a plat-
form for the arrangement of multiple TNF trimers for
simultaneous signaling. The therapeutic use of recom-
binant sTNF has been hampered by its systemic toxicity
and has been limited to localized limb and liver perfu-
sions in certain cancers [11, 12]. TNFR2 agonism may
provide a more targeted immunotherapy with reduced
toxicity because of the more limited cellular expression
of TNFR2. TNFR2 agonists and TNF-inducers have re-
cently emerged as potentially new treatment strategies
for specific and select autoimmune diseases such as mul-
tiple sclerosis and type-1 diabetes. TNF agonism, espe-
cially through the TNFR2 receptor in select autoimmune
disease eliminates autoreactive T cells and induces bene-
ficial T-regulatory cells [13–15].
Additional file 1: Methods description.
Building on our earlier research [13, 15], we set out to
create sTNF muteins with TNFR2 agonism. As a first
step, we created stable trimeric sTNF ligands by introdu-
cing an intermolecular Cys-Cys covalent bond. To our
surprise, the S95C/G148C (TNF07) double mutant, in
addition to being a stable trimer has also shown signifi-
cantly improved TNFR2 signaling even without the
addition of TNFR2 selective mutations. The double mu-
tations in TNF07 (Fig. 1) were chosen after careful con-
sideration of several factors. Ser95 sits on a structurally
conserved beta strand and the isosteric Ser to Cys mutation
Fig. 1 The 3D model of the covalently cross-linked TNF07 mutein. a Top view of the S95C/G148C double mutant. The three monomers are shown in
cartoon representation and the monomers are colored in blue, purple and green. The surface representation is also shown in light grey. Red rectangles
highlight the three Cys-Cys double bonds between each monomer. Residues 95 and 148 are shown in ball and stick representation. b Side view of
the S95C/G148C double mutant. Red rectangle highlights one of the Cys-Cys double bonds and the insert shows the close up view. The model was
generated by Modeller (v.9.12) [24] using the structure of mouse TNF (PDB ID: 2TNF) as the template. The pictures were created by the
program PyMOL [25]
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is one of the most chemically conservative choices. Gly148
is found at the edge of loop 145–147 that participates in
receptor binding but Gly148 itself is not involved in recep-
tor interactions. A comparison of known sTNF structures
shows that the position of residue 148 changes little be-
tween the free and receptor bound forms, maintaining at
all times the ideal distance with residue 95 for S-S double
bond formation. In addition, residues 95 and 148 are hid-
den from the surface (Fig. 1a) and are thus unlikely to in-
duce immunogenicity or cause toxicity, unlike bulky
external additions or chemical cross-linkers [16, 17].
Western blot analysis of the TNF07 mutein confirms a
stable covalent trimer with an apparent molecular weight
of 75 kDa compared to recombinant sTNF with an appar-
ent molecular weight of 25 kDa (Fig. 2). Reduction of the
trimer with dithiothreitol (DTT) resulted in the reappear-
ance of the monomer confirming that trimerization is the
result of disulfide cross-linking and not aggregation
(Fig. 2). The stability of the TNF07 trimer was studied
over a 3 year period. TNF07 muteins stored at −70 °C
remained a stable trimeric structure with single thawing
cycles and re-study on Western blots suggesting the S-S
double bond formations were strong and stable. In com-
parison, recombinant sTNF is only stable for a few
months after reconstitution and storage at −70 °C.
tmTNF is the preferred ligand for TNFR2 signaling. In
contrast, sTNF poorly signals through TNFR2. Past work
has shown murine and human Treg cells expand with
TNFR2 agonism and the TNFR2 receptor is the control-
ling receptor for Treg expansion [15, 18, 19]. We studied
the effects of the new TNF07 mutein in Treg expansion
assays.
In a set of representative flow cytometer pictures from a
single donor, Treg expansion with the new TNF07 mutein
was 7.1 %, with sTNF was 6.9 % or to Il-2 alone at 5.2 %
(Fig. 3a). The TNF07 mutein appeared superior to sTNF
that functions preferentially through TNFR1. As a control
experiment, the same isolated CD4 T cells were also
treated with TNFR2 antagonistic antibodies with resulting
Treg static counts (5.3 %). This experiment was repeated
on 6 additional control CD4 cell samples and statistically
significant differences between the groups were observed
(Fig. 2b). Each time the sTNF exposures to isolated CD4
T cells showed some Treg expansion but each time the
TNF07 mutein was superior at Treg expansion, a feature
of TNFR2 preferential utilization.
To further demonstrate the improved TNFR2 activity
of TNF07, a competitive dose response experiment was
set up with escalating doses of a TNFR2 antagonistic
antibody. The data clearly shows that addition of a
TNFR2 antagonistic antibody in a dose response fashion
blocked TNFR2 agonism and Treg expansion (Fig. 3c).
TNFR2 agonism is an improved proliferative signal for
overall CD8 T cell expansion over TNFR1 or sTNF
signaling. TNFR2 agonism also promotes selective auto-
reactive CD8 T cell directed death in type 1 diabetic cells
[13]. We set out in CD8 proliferative (WST-1) and cell
death (LDH release) assays to functionally test if TNF07
preferentially target TNFR2. In the WST-1 proliferation
assay both control and diabetic CD8 T cells expanded
slightly with media supplemented with IL2 overnight
although the control proliferation was slightly greater
(24+/−2.1 versus 15 +/− 1.7; p = 0.03) (Fig. 4a). The
addition of sTNF equally induced greater proliferation of
control and diabetic CD8 T cells over media (46+/−5.4
versus 41+/−4.1, p = 0.56) (Fig. 4a). In marked contrast,
the application of TNF07, a punitive TNFR2 specific
agonist, to control and type 1 diabetic cells caused
marked CD8 expansion; again the control proliferation
was slightly greater than the type 1 diabetic prolifera-




























Fig. 2 Analysis of TNF and mutein TNF07 on Western Blots under
non-reduced and reduced conditions. Analysis on Western blot
of TNF07 and sTNF under non-reducing conditions reveals sTNF
(right lane) remains a monomer with approximate molecular
weight (MW) of 25kD and the TNF07 (left lane) remains as a
trimer with approximate MW of 75 kDa. With reduction, the
stable TNF07 trimer becomes predominately a monomer with a
25kD MW (center lane)
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Fig. 3 Functional traits of mutein TNF07 compared to sTNF and a TNFR2 antagonistic antibody in CD4 T-regulatory expansion assays. a Flow
cytometry pictures of normal CD4 T cells treated for 16 h with IL-2, IL-2 plus sTNF, IL-2 plus TNF07 or IL-2 plus a TNFR2 antagonistic antibody.
In this prototype experiment, isolated CD4 T cells with IL-2 incubation alone had a basal level of human T regulatory T cells (CD4 + CD25 +
Foxp3+) of 5.2 % after the overnight incubation. In contract, treated with sTNF expanded the Tregs to 6.9 % and TNF07 expanded the Tregs
more successfully to 7.1 %. In contrast, the same cells expanded with IL-2 plus a TNFR2 antibody antagonist showed halted Treg expansion (5.3 %).
b The experiment is (a) was performed a total of 6 times on different CD4 human donors. Data is represented as the % increase or decrease in Treg
cells with sTNF, TNF07 or with the TNFR2 antagonistic antibody compared to IL-2 alone overnight incubations. A = IL2 vs IL2 + Antagonist Ab (p < 0.001),
B = IL2 vs IL2 + TNF-07 (p= 0.0003), C = IL2 vs IL2 + sTNF (p= 0.0027). c An inhibition experiment shows the ability of a monoclonal TNFR2 antagonistic
antibody with dose escalations (ug/ml) to prevent the agonism of the TNF07 mutein
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proliferation data suggested functionally TNF07 was
acting as a TNFR2 agonist for CD8 proliferation.
To further test whether TNF07 was acting as a func-
tional TNFR2 agonist, we sought evidence that the less
robust proliferation of CD8 T cells with TNF or TNF07
in Fig. 4a was due to TNF07 induced autoreactive T cell
death in the diabetic through TNFR2 agonism [13, 15].
It was suspected that TNF or even better the TNF07
mutein was killing a minor subpopulation of autoreac-
tive CD8 T cells in the culture of the type 1 diabetic
cells. To prove this, isolated CD8 T cells were studied in
the LDH cell death assay. In normal donors, CD8 T cells
showed background cell death with either sTNF or
TNF07 (7.3+/−1.5, 8.3+/−0.9, respectively) (Fig. 4b). In
contrast, selective death of autoreactive CD8 T cells of
type 1 diabetic T cells could be observed with sTNF and
even more pronounced with TNF07 (Fig. 4b). This cell
death assay again points to TNF07 showing preferential
TNFR2 signaling.
Here we show that the covalent cross-linking of sTNF
at a strategic location between TNF monomers can gen-
erate a stable trimer with improved functional agonistic
consequences on human CD4 or CD8 T cells. The re-
sults of the human functional T cell assays indicate that
TNF07 has improved TNFR2 agonism, more potent than
sTNF. Internal cross-linking at a different location did
not result in improved TNFR2 activity. TNF07 not only
induced the selective death of autoreactive CD8 T cells in
type-1 diabetic patients, it also demonstrated impressive
proliferation of normal CD8 T cells. TNF07 was also cap-
able of expanding CD4-Treg cells, again a function of
TNFR2 agonism. Various defects in TNF signaling path-
ways occur in both human and mouse models of several
autoimmune disorders. sTNF, TNF inducers or TNFR2
agonism have shown promise for treating these sub-
types of autoimmune diseases [20]. Due to the more
limited expression of TNFR2, TNFR2 agonism provides
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Fig. 4 Proliferation or death of CD8 T cells from type 1 diabetics or controls with sTNF or TNF07 compared to media. The WST-1 cell proliferative
assay or the LDH cell death assay were used to study the effects of TNF or the TNF07 mutein on type 1 diabetic (T1D) or control (CTRL) CD8 T
cells. a. Data shows that CD8 T cell proliferation measured in the WST-1 assays was greater with either TNF and even greater for TNF07 treated
CD8 T cells compared to media alone. Also for each T1D compared to control CD8 T cells the diabetic proliferated was less: this was most pronounced
with the TNF07 mutein. b. In an opposite fashion, cell death measure by LDH assay shows that CD8 diabetic T cells compared to control T cells were
more susceptible to death, especially with TNF07 over sTNF. TNF07 induced death was greater in the type 1 diabetic (p = 0.05). Overall CD8 T cell
proliferation, a trait of agonism of the TNFR2 receptor was greater for TNF07 than TNF and cell death of CD8 autoreactive T cells, a process driven by
CD8 TNFR2 agonism is more pronounced in the diabetic. The data presents 10 normal donors and six type 1 diabetics
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effects. Another TNF construct referred to as TNFR2-
specific sc-TNF variant has been shown to rescue hu-
man neurons from cell death highlighting the potential
application of TNF analogues, especially with preferen-
tial TNFR2 agonism in neurodegenerative diseases [21].
TNFR2 agonism is also known to facilitate diverse
forms of end organ repair [22]. TNF07 was not de-
signed to have TNFR2 selectivity. Future efforts will
focus on removing TNFR1 activity to reduce systemic
toxicity for potential therapeutic applications.
Due to the high structural homology, the concept of
disulfide cross-linking is broadly applicable to all TNFSF
ligands. It provides an alternative to other trimer stabil-
izing methods as a more naturally appearing, and less
immunogenic structure upon human exposure. It is an
expandable system that can be combined with receptor
specific mutations to selectively target various TNFSF re-
ceptors, and also with secondary cross-linking methods of
either the TNFSF ligands or their receptors [6, 7, 23].
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